Covered recipient · General Payments record
THOMAS J GEORGE
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$2,139.61
16 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,764.07 | 7 |
| Food and Beverage | $375.54 | 9 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme Corporation | $1,109.61 | 7 |
| AstraZeneca Pharmaceuticals LP | $1,030.00 | 9 |
Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
THOMAS J GEORGE
NPI 1104867365 · CMS profile ID 321938
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
GAINESVILLE, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1104867365?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104867365?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104867365?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1104867365?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
16 matching records · $2,139.61 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–16 of 16.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corporation | $18.00 | 12/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695910219 | CMS |
| Merck Sharp & Dohme Corporation | $44.00 | 12/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695910225 | CMS |
| Merck Sharp & Dohme Corporation | $49.53 | 12/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695910227 | CMS |
| Merck Sharp & Dohme Corporation | $34.99 | 12/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695912641 | CMS |
| Merck Sharp & Dohme Corporation | $18.16 | 12/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695910221 | CMS |
| Merck Sharp & Dohme Corporation | $194.35 | 12/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695910223 | CMS |
| Merck Sharp & Dohme Corporation | $750.58 | 12/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695910229 | CMS |
| AstraZeneca Pharmaceuticals LP | $32.71 | 11/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709019067 | CMS |
| AstraZeneca Pharmaceuticals LP | $281.99 | 11/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709019165 | CMS |
| AstraZeneca Pharmaceuticals LP | $115.62 | 11/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709019235 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.66 | 11/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709019531 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.04 | 11/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709019579 | CMS |
| AstraZeneca Pharmaceuticals LP | $9.86 | 11/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709019813 | CMS |
| AstraZeneca Pharmaceuticals LP | $47.83 | 11/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709019895 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.00 | 11/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709019921 | CMS |
| AstraZeneca Pharmaceuticals LP | $491.29 | 11/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709019979 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $507,584.60 | 83 |
| PY2024 | Recipient | $2,598.05 | 11 |
| PY2024 | Principal investigator | $596,039.96 | 28 |
| PY2023 | Principal investigator | $1,130,234.11 | 90 |
| PY2022 | Principal investigator | $1,675,365.46 | 75 |
| PY2021 | Principal investigator | $2,129,940.43 | 124 |
| PY2020 | Principal investigator | $2,169,106.03 | 143 |
| PY2019 | Principal investigator | $2,064,075.98 | 203 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
75 records in PY2022
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $111.16 | 12/31/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer | No dispute reported | 06/30/2026 | 940388583 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,065.80 | 12/31/2022 | Non-covered Recipient Entity UF DAVIS CANCER CENTER | A Phase III Study of Pembrolizumab MK-3475 vs. Chemotherapy in Microsatellite Instability-High MSI-H or Mismatch Repair Deficient dMMR Stage IV Colorectal Carcinoma KEYNOTE-177 | No dispute reported | 06/30/2026 | 940404603 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,791.53 | 12/31/2022 | Non-covered Recipient Entity UF DAVIS CANCER CENTER | A Phase III Study of Pembrolizumab MK-3475 vs. Chemotherapy in Microsatellite Instability-High MSI-H or Mismatch Repair Deficient dMMR Stage IV Colorectal Carcinoma KEYNOTE-177 | No dispute reported | 06/30/2026 | 940404605 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $22,125.41 | 12/31/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors | No dispute reported | 06/30/2026 | 940417339 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $174,581.77 | 12/31/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors | No dispute reported | 06/30/2026 | 940417379 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $5,030.24 | 12/31/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors | No dispute reported | 06/30/2026 | 940417527 |
| Principal investigator 1 | Genentech, Inc. | $10,981.00 | 12/13/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II | No dispute reported | 06/30/2026 | 950637381 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $129,150.00 | 12/09/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | No dispute reported | 06/30/2026 | 924865605 |
| Principal investigator 1 | Incyte Corporation | $10,031.70 | 11/30/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 905234567 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $51,660.00 | 11/30/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | No dispute reported | 06/30/2026 | 924865587 |
| Principal investigator 1 | Genentech, Inc. | $26,565.50 | 11/28/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | PHASE I DOSE ESCALATION STUDY OF RO7444973 ON SOLID TUMOURS | No dispute reported | 06/30/2026 | 950638293 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $25,830.00 | 11/21/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | No dispute reported | 06/30/2026 | 924865571 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $13,379.00 | 11/16/2022 | Non-covered Recipient Entity Uf Health Medical Oncology - Davis Cancer Pavilion | Phase I/IIA 2L/3L CRC MSS KRAS Nivo/MEK Combo (trametinib/Novartis) | No dispute reported | 06/30/2026 | 933191027 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $83,919.70 | 11/16/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors | No dispute reported | 06/30/2026 | 940417337 |
| Principal investigator 1 | TerSera Therapeutics LLC | $854.10 | 11/01/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117219 |
| Principal investigator 1 | TerSera Therapeutics LLC | $300.30 | 11/01/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117221 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $25,830.00 | 10/25/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | No dispute reported | 06/30/2026 | 924865513 |
| Principal investigator 1 | Incyte Corporation | $439.00 | 10/21/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 905234551 |
| Principal investigator 1 | Incyte Corporation | $780.00 | 10/21/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 905234553 |
| Principal investigator 1 | Incyte Corporation | $25.00 | 10/21/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 905234555 |
| Principal investigator 1 | Incyte Corporation | $840.00 | 10/21/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 905234557 |
| Principal investigator 1 | Incyte Corporation | $2,340.00 | 10/21/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 905234559 |
| Principal investigator 1 | Incyte Corporation | $650.00 | 10/21/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 905234561 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $64,575.00 | 10/12/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | No dispute reported | 06/30/2026 | 924865479 |
| Principal investigator 1 | Seagen Inc. | $7,940.00 | 10/05/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 917915671 |
| Principal investigator 1 | Seagen Inc. | $6,615.00 | 10/05/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 917915677 |
| Principal investigator 1 | Seagen Inc. | $8,298.00 | 10/05/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 917915681 |
| Principal investigator 1 | Seagen Inc. | $227.50 | 10/05/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 917915687 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,161.58 | 09/14/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A SCREENING PROTOCOL TO SUPPORT PRELIMINARY ELIGIBILITY FOR CLINICAL T | No dispute reported | 06/30/2026 | 943936253 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,550.00 | 09/02/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A SCREENING PROTOCOL TO SUPPORT PRELIMINARY ELIGIBILITY FOR CLINICAL T | No dispute reported | 06/30/2026 | 943936255 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $25,830.00 | 08/30/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | No dispute reported | 06/30/2026 | 924866345 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $51,660.00 | 08/26/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | No dispute reported | 06/30/2026 | 924866339 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $51,660.00 | 08/23/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | No dispute reported | 06/30/2026 | 924866305 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,864.40 | 08/12/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A SCREENING PROTOCOL TO SUPPORT PRELIMINARY ELIGIBILITY FOR CLINICAL T | No dispute reported | 06/30/2026 | 943936257 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $3,888.00 | 08/10/2022 | Non-covered Recipient Entity UF DAVIS CANCER CENTER | A Phase III Study of Pembrolizumab MK-3475 vs. Chemotherapy in Microsatellite Instability-High MSI-H or Mismatch Repair Deficient dMMR Stage IV Colorectal Carcinoma KEYNOTE-177 | No dispute reported | 06/30/2026 | 940404601 |
| Principal investigator 1 | Seagen Inc. | $890.50 | 08/03/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | A Phase 1 Study of SGN-STNV in Advanced Solid Tumors | No dispute reported | 06/30/2026 | 917915601 |
| Principal investigator 1 | TerSera Therapeutics LLC | $2,509.65 | 07/26/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117217 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $51,660.00 | 07/15/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | No dispute reported | 06/30/2026 | 924866269 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $30,996.00 | 07/06/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | No dispute reported | 06/30/2026 | 924866245 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $51,660.00 | 06/27/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | No dispute reported | 06/30/2026 | 924865795 |
| Principal investigator 1 | Seagen Inc. | $5,265.00 | 06/22/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 917915459 |
| Principal investigator 1 | Seagen Inc. | $1,300.00 | 06/22/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 917915475 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $46,494.00 | 06/13/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | No dispute reported | 06/30/2026 | 924865733 |
| Principal investigator 1 | TerSera Therapeutics LLC | $4,001.40 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117193 |
| Principal investigator 1 | TerSera Therapeutics LLC | $260.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117195 |
| Principal investigator 1 | TerSera Therapeutics LLC | $650.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117197 |
| Principal investigator 1 | TerSera Therapeutics LLC | $65.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117199 |
| Principal investigator 1 | TerSera Therapeutics LLC | $3,902.60 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117201 |
| Principal investigator 1 | TerSera Therapeutics LLC | $6,890.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117203 |
| Principal investigator 1 | TerSera Therapeutics LLC | $421.85 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117205 |
| Principal investigator 1 | TerSera Therapeutics LLC | $3,900.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117207 |
| Principal investigator 1 | TerSera Therapeutics LLC | $1,235.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117209 |
| Principal investigator 1 | TerSera Therapeutics LLC | $1,430.00 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117211 |
| Principal investigator 1 | TerSera Therapeutics LLC | $3,038.10 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117213 |
| Principal investigator 1 | TerSera Therapeutics LLC | $227.50 | 06/07/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117215 |
| Principal investigator 1 | TerSera Therapeutics LLC | $1,625.00 | 06/01/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117191 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $25,830.00 | 05/27/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | No dispute reported | 06/30/2026 | 924865727 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $38,745.00 | 05/25/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | No dispute reported | 06/30/2026 | 924865721 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $53,405.50 | 05/10/2022 | Non-covered Recipient Entity NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT FOUNDATION, INC | A Phase II Study to Assess the Activity of PD-L1 Inhibition with Durvalumab after Chemo-Radiotherapy in Patients with Stage II-IV Microsatelite Stable (MSS) Rectal Cancer | No dispute reported | 06/30/2026 | 914599239 |
| Principal investigator 1 | TerSera Therapeutics LLC | $2,495.35 | 05/05/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117189 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $12,915.00 | 05/02/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | No dispute reported | 06/30/2026 | 924865715 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $23,178.50 | 04/22/2022 | Non-covered Recipient Entity University Of Florida College Of Medicine | Ph I IIA 2L 3L CRC MSS KRAS Nivo MEK Combo trametinib Novartis | No dispute reported | 06/30/2026 | 933189093 |
| Principal investigator 1 | Seagen Inc. | $899.60 | 04/06/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 917915465 |
| Principal investigator 1 | Seagen Inc. | $5,098.72 | 04/06/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | No dispute reported | 06/30/2026 | 917915471 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $38,745.00 | 04/05/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | No dispute reported | 06/30/2026 | 924865710 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $12,915.00 | 03/23/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Nal-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal-IRI Study) | No dispute reported | 06/30/2026 | 924865869 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $129,150.00 | 03/23/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Nal-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal-IRI Study) | No dispute reported | 06/30/2026 | 924865875 |
| Principal investigator 1 | Amgen Inc. | $97.50 | 03/22/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA HEALTH | CB100 Dose Comparison Study | No dispute reported | 06/30/2026 | 942841067 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $31,014.00 | 02/16/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Nal-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal-IRI Study) | No dispute reported | 06/30/2026 | 924865847 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $20,676.00 | 02/15/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Nal-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal-IRI Study) | No dispute reported | 06/30/2026 | 924865789 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $25,830.00 | 02/15/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Nal-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal-IRI Study) | No dispute reported | 06/30/2026 | 924865853 |
| Principal investigator 1 | TerSera Therapeutics LLC | $1,248.00 | 02/01/2022 | Non-covered Recipient Entity UNIVERSITY OF FLORIDA (416) | A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer | No dispute reported | 06/30/2026 | 954117187 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,340.00 | 01/20/2022 | Non-covered Recipient Entity University Of Florida | Phase I IIA 2L 3L CRC MSS KRAS Nivo MEK Combo trametinib Novartis | No dispute reported | 06/30/2026 | 933190767 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $129,150.00 | 01/03/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Nal-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal-IRI Study) | No dispute reported | 06/30/2026 | 924865859 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $51,660.00 | 01/03/2022 | Non-covered Recipient Entity University of Florida Board of Trustees | A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Nal-IRI in Combination with 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal-IRI Study) | No dispute reported | 06/30/2026 | 924865865 |